LtaS-IN-1;Naphtho[2,1-b]furan-1-acetic acid, 2-oxo-2-[(5-phenyl-1,3,4-oxadiazol-2-yl)amino]ethyl ester;(5-phenyl-1,3,4-oxadiazol-2-yl)carbamoyl]methyl 2-{naphtho[2,1-b]furan-1-yl}acetate;2-oxo-2-((5-phenyl-1,3,4-oxadiazole-2-yl)amino-)ethyl 2-(naphtho[2,1-b]furo-1-yl)acetate;Bacterial,MDR,E. faecium,LtaSIN1,multidrug-resistant,inhibit,LtaS IN 1,anti-bacterial,Inhibitor;LtaS-IN-1, 10 mM in DMSO;2-Oxo-2-((5-phenyl-1,3,4-oxadiazol-2-yl)amino)ethyl 2-(naphtho[2,1-b]furo-1-yl)-acetate
LtaS-IN-1 is a potent small-molecule inhibitor of lipoteichoic acid (LTA) biosynthesis, effective against multidrug-resistant (MDR) Enterococcus spp., including E. faecium; it inhibits bacterial growth with MIC values ranging from 0.5 μg/mL to 64 μg/mL; it exhibits synergistic antibacterial activity when combined with antibiotics such as ampicillin, gentamicin, linezolid, daptomycin, or vancomycin, leading to 97–100% growth inhibition of MDR strains; it also alters cell wall morphology and suppresses the growth of specific strains (e.g., E1630 and E1590) with MICs of 0.5 μg/mL.